We are committed to finding a cure for WM.

Article: Selecting Initial Therapy for Newly Diagnosed Waldenstrom Macroglobulinemia

Article Abstract:

In the article that accompanies this editorial, Treon and colleagues
1 report on 30 newly diagnosed patients with Waldenstr¨om
macroglobulinemia (WM) treated with ibrutinib. Clinically relevant
responses were seen in all patients. Responses occurred rapidly
with an 18-month progression-free survival (PFS) of 92%. Their
article, along with the recently published article by Dimopoulos
et al2 (NCT02165397; iNNOVATE Study: A Randomized, Double-
Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in
Combination With Rituximab in Subjects With Waldenstr¨om’s
Macroglobulinemia), which demonstrated a significantly higher
response rate, deeper responses, and superior PFS with the combination
of ibrutinib and rituximab compared with rituximab alone,
firmly establishes ibrutinib as a reasonable choice for the treatment
of newly diagnosed WM.

Click the link below to download the full Editorial and Article

Selecting Initial Therapy for WM – 2018 publication in the Journal of Clinical Onclogy